Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on September 24, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 5.02 (Departure/Election of Directors or Officers). Two directors appointed September 22, 2026, filling vacancies and expanding the Board to nine members.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Two directors appointed September 22, 2026, filling vacancies and expanding the Board to nine members
- Senator Torricelli joins the Audit Committee, adding healthcare and governance experience
- Dr. Miller joins the Clinical Committee, bringing Medicare policy, regulation and health-plan expertise
- Each receives a pro rata 2026 retainer and RSUs valued at $200,000, prorated through December 31, 2026
- Appointments strengthen oversight amid healthcare regulatory and clinical governance demands
Item EX-99.1 · Exhibit EX-99.1
- Former Senator Robert Torricelli and Dr. Brian J. Miller appointed directors, filling two vacancies
- Board expanded to nine directors, strengthening governance capacity
- Torricelli joins Audit Committee with federal healthcare policy and Clover subsidiary experience
- Miller joins Clinical Committee, adding Medicare payment, regulatory, and practicing physician expertise
- Appointments support Clover’s Medicare Advantage strategy but create no disclosed immediate financial impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.